Search results
Results from the WOW.Com Content Network
Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, [9] [11] but discontinued for use in triple-negative breast cancer (TNBC). [12]
The subcutaneous injection of atezolizumab and hyaluronidase was evaluated in IMscin001 (NCT03735121), an open-label, multi-center, international, randomized trial in adults with locally advanced or metastatic non-small cell lung cancer who were not previously exposed to cancer immunotherapy and who had disease progression following treatment with platinum-based chemotherapy. [2]
Therapeutic, diagnostic and preventive monoclonal antibodies are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab.
NSCLC cells expressing programmed death-ligand 1 (PD-L1) could interact with programmed death receptor 1 (PD-1) expressed on the surface of T cells and result in decreased tumor cell kill by the immune system. Atezolizumab is an anti-PD-L1 monoclonal antibody. Nivolumab and Pembrolizumab are anti-PD-1 monoclonal antibodies.
The study enrolled 34 patients, 28 of which underwent surgery to resect the PDAC. 19 of the patients who had undergone surgery then received atezolizumab, an immune checkpoint inhibitor. 16 of the patients on atezolizumab then received autogene cevumeran. 1 patient was considered to have insufficiently many neoantigens to manufacture the vaccine.
Each antibody binds only one specific antigen. Monoclonal antibodies (mAbs) have varied therapeutic uses. It is possible to create a mAb that binds specifically to almost any extracellular target, such as cell surface proteins and cytokines.
Median OS was 19.8 and 14.9 months for patients treated with chemotherapy plus Bevacizumab, with or without atezolizumab, respectively. [61] [60] [16] Median OS with Atezolizumab and chemotherapy alone was 19.5 months, [60] raising question with regard to the added value of Bevacizumab to this combination for the general patients population. [16]
Atezolizumab (Tecentriq) is a fully humanised IgG1 (immunoglobulin 1) antibody developed by Roche Genentech. In 2016, the FDA approved atezolizumab for urothelial carcinoma and non-small cell lung cancer. Avelumab (Bavencio) is a fully human IgG1 antibody developed by Merck Serono and Pfizer.